- Report
- April 2025
- 50 Pages
Global
From €2420EUR$2,650USD£2,070GBP
- Report
- April 2025
- 50 Pages
Global
From €2420EUR$2,650USD£2,070GBP
Voglibose is a drug used to treat endocrine and metabolic disorders. It is a hypoglycemic agent, meaning it helps to lower blood sugar levels. It is used to treat type 2 diabetes, as well as other conditions such as obesity and polycystic ovary syndrome. Voglibose works by slowing down the absorption of carbohydrates from the intestine, which helps to reduce the amount of glucose in the blood. It is usually taken in combination with other medications, such as insulin or metformin.
Voglibose is available in both tablet and oral solution form. It is generally well tolerated, with few side effects. Common side effects include nausea, vomiting, and abdominal pain. It is important to follow the instructions of your doctor when taking Voglibose.
The Voglibose market is highly competitive, with many companies offering their own versions of the drug. Some of the major players in the market include Novo Nordisk, Sanofi, Merck, and Pfizer. Show Less Read more